IP Library Granted Patent US 11,071,583
Granted Patent B2
US 11,071,583 · App. 15/008,103 · Granted Jul 27, 2021

Power generating and control apparatus for the treatment of tissue

Inventors: Bret Herscher (Cupertino, CA); David Krawzsenek (El Cajon, CA); Aaron LeBarge (San Diego, CA); Joseluis Espinosa (San Diego, CA); Michael Perry (Los Altos, CA)
Assignee: BOSTON SCIENTIFIC SCIMED, INC.
A61B18/1492A61B18/1206A61B17/22012A61B18/245A61B2018/0022A61B2018/00214A61B2018/00422A61B2018/00434A61B2018/00577A61B2018/00642A61B2018/00684A61B2018/00702A61B2018/00875A61B2018/00898A61B2018/1861A61N7/022
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,071,583
App. No.
15/008,103
Granted
Jul 27, 2021
Kind
B2
Abstract

Apparatus, systems, and methods are provided for the generation and control of energy delivery in a dosage to elicit a therapeutic response in diseased tissue. A balloon catheter can have electrodes attached to a power generator and controller such that the balloon and electrodes contact tissue during energy treatment. Energy selectively may be applied to tissue based on measured impedance to achieve gentle heating. Calibration of the apparatus and identification of attached accessories by computing the circuit impedance prior to energy dosage facilitate regulation of power delivery about a set point. Energy delivery can be controlled to achieve substantially uniform bulk tissue temperature distribution. Energy delivery may beneficially affect nerve activity.

Claims (38)

1. A method for the delivery of energy in tissue comprising the steps of:

positioning a plurality of energy delivery surfaces proximate to the tissue;

applying a first energy dosage to the tissue by powering a first portion of the plurality of energy delivery surfaces in a sequenced pattern;

applying a second energy dosage to the tissue by powering a second portion of the plurality of energy delivery surfaces in a sequenced pattern; and

measuring tissue impedance at a point of power delivery and applying the first and second energy dosages such that measured tissue impedance is maintained about constant, thereby resulting in a uniform temperature distribution in the tissue through the sensing of impedance at the point of power delivery;

wherein the first and second portions of the plurality of energy delivery surfaces are powered by a power amplifier that has a soft current limit such that available output voltage decreases as output current is increased.

2. The method of claim 1 , wherein the plurality of energy delivery surfaces are operatively coupled to a power generation and control apparatus further comprising: a DDS operatively coupled to the power amplifier; a power output set point controller providing a signal; a power sensor receiving voltage and current feedback measured at a power delivery target and providing a signal based on the feedback; and a PID controller, operatively coupled to receive the signals from the power output set point controller and the power sensor, and operatively coupled to direct a modulating voltage signal to the power amplifier, such that power output is maintained within a range about the power output set point in response to measured impedance at the power delivery target.

3. The method of claim 2 , wherein the DDS, power output set point controller, and peak effective power sensor comprise a field programmable gate array.

4. The method of claim 2 , wherein the signal from the power sensor represents the effective power output at the power delivery target.

5. The method of claim 2 , wherein an available range of the power output set point is between about 0.001 Watts to about 50 Watts.

6. The method of claim 1 , wherein the first and second energy dosage delivered to the tissue is RF energy.

7. The method of claim 1 , wherein the energy delivery surfaces include electrodes carried on a distal end of an elongate catheter.

8. The method of claim 1 , comprising positioning the plurality of energy delivery surfaces proximate to a targeted tissue region containing nerves therein.

9. The method of claim 8 , further comprising characterizing the location of nerves in the tissue region by measuring the impedance of tissue proximate to the plurality of energy delivery surfaces.

10. The method of claim 8 , wherein the first and second energy dosages disrupt conduction of nerve signals in the tissue region by denaturing the conductive properties of nerves in the tissue region.

11. The method of claim 8 , wherein the first and second energy dosages permanently disrupt conduction of nerve signals in the tissue region by ablating nerves in the tissue region.

12. The method of claim 8 , wherein power output is limited to occur at a measured impedance of tissue in the tissue region between about 50 Ohms to about 500 Ohms.

13. A method for the delivery of energy in tissue comprising the steps of:

positioning a plurality of energy delivery surfaces proximate to the tissue;

applying a first energy dosage to the tissue by powering a first portion of the plurality of energy delivery surfaces in a sequenced pattern;

applying a second energy dosage to the tissue by powering a second portion of the plurality of energy delivery surfaces in a sequenced pattern; and

measuring tissue impedance;

wherein the plurality of energy delivery surfaces are operatively coupled to a power generation and control apparatus further comprising: a DDS operatively coupled to a power amplifier; a power output set point controller providing a signal; a power sensor receiving voltage and current feedback measured at a power delivery target and providing a signal based on the feedback; and a PID controller, operatively coupled to receive the signals from the power output set point controller and the power sensor, and operatively coupled to direct a modulating voltage signal to the power amplifier, such that power output is maintained within a range about the power output set point in response to the measured impedance at the power delivery target; and

wherein the power amplifier is comprised of a variable gain amplifier and a linear power amplifier operatively coupled in series.

14. The method of claim 13 , wherein output voltage during use comprises RF output voltage having a maximum available output limit over a range of load impedances of about 50 Ohms to about 500 Ohms.

15. A method for the delivery of energy in tissue comprising the steps of:

positioning a plurality of energy delivery surfaces proximate to the tissue at targeted tissue region containing nerves therein;

applying a first energy dosage to the tissue by powering a first portion of the plurality of energy delivery surfaces in a sequenced pattern;

applying a second energy dosage to the tissue by powering a second portion of the plurality of energy delivery surfaces in a sequenced pattern; and

measuring tissue impedance at a point of power delivery and applying the first and second energy dosages such that measured tissue impedance is maintained about constant, thereby resulting in a uniform temperature distribution in the tissue through the sensing of impedance at the point of power delivery;

wherein the energy delivery surfaces include electrodes carried on a distal end of an elongate catheter;

wherein the first and second energy dosage delivered to the tissue is RF energy; and

wherein the first and second portions of the plurality of energy delivery surfaces are powered by a power amplifier that has a soft current limit such that available output voltage decreases as output current is increased.

16. The method of claim 15 , further comprising characterizing the location of nerves in the tissue region by measuring the impedance of tissue proximate to the plurality of energy delivery surfaces.

17. The method of claim 15 , wherein the first and second energy dosages disrupt conduction of nerve signals in the tissue region by denaturing the conductive properties of nerves in the tissue region.

18. The method of claim 15 , wherein the first and second energy dosages permanently disrupt conduction of nerve signals in the tissue region by ablating nerves in the tissue region.

19. The method of claim 15 , wherein power output is limited to occur at a measured impedance of tissue in the tissue region between about 50 Ohms to about 500 Ohms.

20. The method of claim 15 , wherein the plurality of energy delivery surfaces are operatively coupled to a power generation and control apparatus further comprising: a DDS operatively coupled to the power amplifier; a power output set point controller providing a signal; a power sensor receiving voltage and current feedback measured at a power delivery target and providing a signal based on the feedback; and a PID controller, operatively coupled to receive the signals from the power output set point controller and the power sensor, and operatively coupled to direct a modulating voltage signal to the power amplifier, such that power output is maintained within a range about the power output set point in response to measured impedance at the power delivery target.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2020
From: HERSCHER, BRET; KRAWZSENEK, DAVID; LABARGE, AARON; ESPINOSA, JOSELUIS; PERRY, MICHAEL
To: MINNOW MEDICAL, INC.
Reel/Frame 051417/0280 →
CHANGE OF NAME Recorded Jan 5, 2020
From: MINNOW MEDICAL, INC.
To: VESSIX VASCULAR, INC.
Reel/Frame 051417/0296 →
NUNC PRO TUNC ASSIGNMENT Recorded Jan 5, 2020
From: VESSIX VASCULAR, INC.
To: BOSTON SCIENTIFIC SCIMED, INC.
Reel/Frame 051417/0306 →
Continuity (3)
Continuation 13066347 · Apr 11, 2011
Provisional Application 61342191 · Apr 9, 2010
Related Publication 20160135883A1 · May 19, 2016